Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Conditions: Multiple Myeloma; Neoplasm, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorder; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Antineoplastic Agents; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs
Intervention: Biological: CYNK-001
Sponsor: Celularity Incorporated
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
March 17, 2020 /
/ in Oncology